FC游戏站:为您提供一个绿色免费的下载空间! 首页| 电脑软件| 安卓 | 手机网站
当前位置:首页 > FC游戏动态 > Kosan Biosciences to Present at the Cowen and Company 28th A

Kosan Biosciences to Present at the Cowen and Company 28th A

来源:FC游戏站 更新:2020-11-17

用手机看

扫描二维码随时看1.在手机上浏览
2.分享给你的微信好友或朋友圈


  HAYWARD, Calif., March 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN - News) announced today that Gary S. Titus, Kosan''s Senior Vice President and Chief Financial Officer, will present at the Cowen and Company 28th Annual Health Care Conference in Boston at the Boston Marriott Copley Place on Wednesday, March 19, 2008 at 8:00 a.m. Eastern Time. A live webcast of the presentation can be accessed through ?ticker=KOSN&item_id=1786588.

Interested parties may also access a live webcast of the presentation by visiting the "Events Calendar" page under the "Investors/Press" tab on Kosan''s website at A recorded replay of the presentation will be available for two weeks.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade®) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with trastuzumab (Herceptin?). Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan''s motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit the company''s website at

Velcade? (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin? (trastuzumab) is a registered trademark of Genentech, Inc.

Source: Kosan Biosciences Incorporated
  

,FC,NES,NES

猜你感兴趣